A significant number of patients with moderate to severe atopic dermatitis (AD) failed to achieve adequate disease control with systemic therapies over 12 months, indicating a substantial degree of "therapeutic inertia."
An intracameral implant that releases travoprost into the eye over an extended period to lower intraocular pressure in glaucoma and ocular hypertension will be available commercially in early 2024.
An early trial suggests a combination of psilocybin and psychotherapy may be safe and effective for treatment-resistant depression associated with bipolar II disorder and deserves further study.
Patients with transthyretin amyloid cardiomyopathy taking tafamidis have less worsening of cardiac function than those on placebo, post hoc analysis of randomized results suggests.